Connect with industry leaders, expand your network, and benefit from exclusive access to industry updates. Discover new opportunities in a seamless, interactive learning environment. Elevate your experience with us!
2026 Is the Year of E6(R3) Enforcement — Will Your RBQM Strategy Be Inspection-Ready?
The 6th Risk-Based Quality Management Summit is the only meeting dedicated to real-world, post-E6(R3) implementation. Learn directly from AbbVie, Eli Lilly, Gilead, Takeda, and Tufts CSDD experts on what’s working, what’s failing, and how to prove ROI to leadership.
Join peers in Philadelphia on January 13–14, 2026 for two full days of practical guidance, ready-to-use templates, and lessons learned from early adopters so your team enters 2026 confident and compliant.
Sessions will spotlight how to:
- Implement QbD that drives measurable outcomes across every trial phase
- Overcome cultural and change-management barriers to lasting RBQM adoption
- Harness AI, audit trail analytics, and advanced metrics for proactive risk detection
- Translate ICH E6(R3) compliance into operational and strategic wins
- Quantify the financial ROI of RBQM deployments with new Tufts CSDD research
- Build and staff the “dream team” needed for a post-E6(R3) world
RBM/ RBQM
- Study Monitoring
- Clinical Research
- Clinical Protocol Lead
- Clinical Standards and Innovation
- Research Quality
- R&D Quality
- Regulatory Affairs
- Study Lead
- Clinical Quality
- Clinical Operations & Compliance
- GCP Quality Assurance
- Clinical Outsourcing Analytics
- Trial Feasibility
- Central Monitoring/Site Monitoring
- Clinical Quality Assurance
- Risk Evaluation & Adaptive Integrated Monitoring
- Data Management
- Site Engagement
- Clinical Business Operations
- Clinical Operations
- Clinical Research Compliance
- Risk/Risk Management
- Data Monitoring
- Site Monitoring
- Data Sciences
